Sensitivity of KRAS-Mutant colorectal cancers to combination therapy that cotargets MEK and CDK4/6

Clinical Cancer Research

Volumn 22, Issue 2, 2016, Pages 405-414

  Ziemke, Elizabeth K ^a   Dosch, Joseph S ^a   Maust, Joel D ^a   Shettigar, Amrith ^a   Sen, Ananda ^a   Welling, Theodore H ^a   Hardiman, Karin M ^a   Sebolt Leopold, Judith S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PALBOCICLIB; RETINOBLASTOMA PROTEIN; TRAMETINIB; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HCT116 CELL LINE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; COLORECTAL NEOPLASMS; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; MUTATION; NUDE MOUSE; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DRUG THERAPY, COMBINATION; FEMALE; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84959020489     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0829     Document Type: Article

References (27)

1. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: The search continues. Future Med Chem 2011;3:1787-808.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
4. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715-21.
5. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
6. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-61.
7. MeyersonM,HarlowE. Identification ofG1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994;14:2077-86.
8. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010;18:63-73.
9. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012;18:1503-10.
10. Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, Van Den Brink GR, et al. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 2010;70: 8149-58.
11. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299-304.
12. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylationspecific PCR: A novel PCR assay formethylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
14. Fry DW, Harvey PJ, Keller PR, Elliott WL,MeadeM, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3: 1427-38.
15. Zhao Y, Adjei AA. The clinical development ofMEKinhibitors. Nat Rev Clin Oncol 2014;11:385-400.
16. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkami SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
17. Chou T. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
18. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of theMAPkinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6.
19. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93.
20. Wright CJM,McCormack PL. Trametinib: First global approval. Drugs 2013; 73:1245-54.
21. Lito P, Saborowski A, Yue J, SolomonM, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 2014;25:697-710.
22. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005;17: 215-24.
23. Yu J, Wu WKK, Li X, He J, Li XX, Ng SSM, et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut 2015; 64:636-45.
24. Sosman JA, Kittaneh M, LolkemaMP, Postow MA, Schwartz G, Franklin C, et al. A phase Ib/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: EaRlY EnCoUrAgInG ClInIcal activity. J Clin Oncol 2014;32:5s (suppl; abstr 9009).
25. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
26. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010;70:6804-14.
27. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012;18:2515-25.